Ulisse Biomed S.p.A. and Ikonysis SA, a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, are pleased to announce a strategic collaboration to enhance their technical and commercial capabilities in cancer diagnostics.
A key aspect of this collaboration is the integration of UBM’s expertise in Molecular Biology alongside with Ikonisys’ Liquid-Based Cytology (LBC) and Fluorescence In Situ Hybridization (FISH) technology. This integration is set to provide innovative cancer diagnostics by offering comprehensive and precise diagnostic capabilities that can greatly enhance patient outcomes. In the framework of this partnership:
- The Companies will explore cross-selling and co-marketing opportunities through their sales networks to maximize market penetration and leverage product and service synergies. A mutual distribution agreement will be defined in a second step.
- Ikonisys and UBM are committed to working together to explore and develop new business opportunities. This partnership reflects their shared goal of innovating and growing by combining skills and resources. A technical deep dive will also thus be conducted to discuss potential production and OEM agreements, aiming to optimize production techniques and ensure high product quality. This initiative will integrate the technical expertise of both Companies, promoting innovative and competitive solutions in cancer diagnostics.
The partnership will first take place with the installation and mutual training of instruments at Hospitex Lab in Florence, part of the IKONISYS Group , which is scheduled between end of June and mid-July. Thanks to this cooperation, the Companies will be able to familiarize themselves with each other's technologies and expertise, fostering closer technical cooperation.
In Autumn 2024, Ikonisys and UBM will co-organize a demo day to showcase their technologies and products to customers. This event will be the opportunity to assess the added value of their collaboration, allowing direct interaction with customers, gathering feedback, and thus identifying market opportunities.
Nicola Basile, CEO of Ulisse Biomed, stated: “We consider Ikonisys a partner with many strategical fits with UBM Group, from a technological perspective to a commercial synergy. We foresee a great collaboration ahead. In the last months, we have been working on our integration with Hyris and this partnership confirms we are on the right path to be a relevant player in the market with significant solutions for customers and prospects.”
Mario Crovetto, CEO of Ikonisys, added: “UBM’s innovative technology and vision are perfectly aligned to Ikonisys’ development strategy, especially with the recent integration of Hyris. Following the announcement of Hospitex integration on our end, which is still ongoing, this partnership attests of our relentless commitment to further maximizing value for our shareholders and offering integrated and accurate diagnostics solutions to our customers. By joining forces with UBM, we are positioned to accelerate our growth strategy, by further broadening our core business and expanding our sales network.”